Abstract Rituximab (MabThera®, Rituxan®) is a chimeric mouse anti-human CD20
monoclonal antibody. This article reviews the use of intravenous rituximab in the treatment of …

In a previous systematic review and meta-analysis of five randomized controlled trials
comparing rituximab maintenance with no maintenance (observation or rituximab at …

In the past 15 years, treatment outcomes for hematologic malignancies have improved
substantially. However, drug prices have also increased drastically. This commentary …

Background Few studies have estimated the real-world economic burden such as all-cause
and follicular lymphoma (FL)-related costs and health care resource utilization (HCRU) in …

Background. The individual concerns of non-Hodgkin's lymphoma (NHL) patients require
identification and assessment during clinical research proposing to measure patients' …

Purpose: As costs of cancer care rise, there has been a shift to focus on value. Drug wastage
affects costs to patients and health care systems without adding value. Historically, cost …

Decision makers increasingly request evidence on the real-world cost effectiveness of a new
treatment. There is, however, a lack of practical guidance on how to conduct an economic …

Background: Rituximab maintenance therapy was shown to significantly extend overall
survival (OS) and progression-free survival (PFS) in relapsed/refractory follicular lymphoma …

Background Rituximab induction together with CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone) and rituximab maintenance (RCHOP-R) resulted to significant …

OBJECTIVES: In this study, the cost-effectiveness of rituximab was evaluated in comparison
with commonly used chemotherapy regimens for patients with advanced follicular lymphoma …